$38.8
Collegium Pharmaceutical is a drug manufacturers - specialty & generic business based in the US. Collegium Pharmaceutical shares (COLL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $39.34 – an increase of 7.37% over the previous week. Collegium Pharmaceutical employs 197 staff and has a trailing 12-month revenue of around $576.7 million.
What's in this guide?
Our top picks for where to buy Collegium Pharmaceutical stock
- Earn 4.5% interest on uninvested cash with Gold
- Get up to $50,000 in instant deposits with Gold
- Easy, user-friendly trading
- Unlimited bonus amounts Oct 16-27
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Collegium Pharmaceutical stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – COLL. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Collegium Pharmaceutical stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Collegium Pharmaceutical stock price (NASDAQ: COLL)
Use our graph to track the performance of COLL stocks over time.Collegium Pharmaceutical shares at a glance
Latest market close | $39.34 |
---|---|
52-week range | $20.95 - $42.29 |
50-day moving average | $37.34 |
200-day moving average | $35.29 |
Wall St. target price | $43.25 |
PE ratio | 14.485 |
Dividend yield | N/A |
Earnings per share (TTM) | $2.66 |
Is it a good time to buy Collegium Pharmaceutical stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Collegium Pharmaceutical price performance over time
Historical closes compared with the close of $38 from 2024-10-14
1 week (2024-10-10) | 3.71% |
---|---|
1 month (2024-09-17) | 1.66% |
3 months (2024-07-17) | 18.97% |
6 months (2024-04-17) | 7.19% |
1 year (2023-10-17) | 73.04% |
---|---|
2 years (2022-10-17) | 108.22% |
3 years (2021-10-15) | 81.12% |
5 years (2019-10-17) | 214.57% |
Is Collegium Pharmaceutical stock undervalued or overvalued?
Valuing Collegium Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Collegium Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Collegium Pharmaceutical's P/E ratio
Collegium Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Collegium Pharmaceutical shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Collegium Pharmaceutical's EBITDA
Collegium Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $347.4 million.
The EBITDA is a measure of a Collegium Pharmaceutical's overall financial performance and is widely used to measure a its profitability.
Collegium Pharmaceutical financials
Revenue TTM | $576.7 million |
---|---|
Operating margin TTM | 32.68% |
Gross profit TTM | $345.7 million |
Return on assets TTM | 11.24% |
Return on equity TTM | 47.87% |
Profit margin | 17.32% |
Book value | $6.70 |
Market Capitalization | $1.2 billion |
TTM: trailing 12 months
Collegium Pharmaceutical share dividends
We're not expecting Collegium Pharmaceutical to pay a dividend over the next 12 months.
Collegium Pharmaceutical share price volatility
Over the last 12 months, Collegium Pharmaceutical's shares have ranged in value from as little as $20.95 up to $42.2873. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Collegium Pharmaceutical's is 0.932. This would suggest that Collegium Pharmaceutical's shares are less volatile than average (for this exchange).
Collegium Pharmaceutical overview
Collegium Pharmaceutical, Inc. , a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc.
Frequently asked questions
nullWhat percentage of Collegium Pharmaceutical is owned by insiders or institutions?
Currently 1.317% of Collegium Pharmaceutical shares are held by insiders and 125.895% by institutions. How many people work for Collegium Pharmaceutical?
Latest data suggests 197 work at Collegium Pharmaceutical. When does the fiscal year end for Collegium Pharmaceutical?
Collegium Pharmaceutical's fiscal year ends in December. Where is Collegium Pharmaceutical based?
Collegium Pharmaceutical's address is: 100 Technology Center Drive, Stoughton, MA, United States, 02072 What is Collegium Pharmaceutical's ISIN number?
Collegium Pharmaceutical's international securities identification number is: US19459J1043 What is Collegium Pharmaceutical's CUSIP number?
Collegium Pharmaceutical's Committee on Uniform Securities Identification Procedures number is: 19459J104
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
eToro review 2024: Commission-free social trading and investing
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Titan Review 2024: Wealth Management With a No-Advisory-Fee Robo-Advisor
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question